Department of Medicine, University of California, San Francisco, CA, USA.
Am Heart J. 2011 Sep;162(3):555-61. doi: 10.1016/j.ahj.2011.05.023. Epub 2011 Aug 9.
We sought to evaluate the prognostic performance of the CHADS(2) score for prediction of ischemic stroke/transient ischemic attack (TIA) in subjects with coronary heart disease (CHD) without atrial fibrillation (AF).
In 916 nonanticoagulated outpatients with stable CHD and no AF by baseline electrocardiogram, we calculated CHADS(2) scores (congestive heart failure, hypertension, age ≥75 years, diabetes [1 point each], and prior stroke or TIA [2 points]). The primary outcome was time to ischemic stroke or TIA over a mean follow-up of 6.4 ± 2.3 years.
Over 5,821 person-years of follow-up, 40 subjects had an ischemic stroke/TIA (rate 0.69/100 person-years, 95% CI 0.50-0.94). Compared with subjects with low (0-1) CHADS(2) scores, those with intermediate (2-3) and high (4-6) CHADS(2) scores had an increased rate of stroke/TIA, even after adjustment for age, tobacco, antiplatelet therapy, statins, and angiotensin inhibitors (CHADS(2) score 2-3: HR 2.4, 95% CI 1.1-5.3, P = .03; CHADS(2) score 4-6: HR 4.0, 95% CI 1.5-10.6, P = .006). Model discrimination (c-statistic = 0.65) was comparable with CHADS(2) model fit in published AF-only cohorts.
The CHADS(2) score predicts ischemic stroke/TIA in subjects with stable CHD and no baseline AF. The event rate in non-AF subjects with high CHADS(2) scores (5-6) was comparable with published rates in AF patients with moderate CHADS(2) scores (1-2), a population known to derive benefit from stroke prevention therapies. These findings should inform efforts to determine whether stroke prevention therapies or screening for silent AF may benefit subjects with stable CHD and high CHADS(2) scores.
我们旨在评估 CHADS₂ 评分在无房颤(AF)的冠心病(CHD)患者中预测缺血性卒中/短暂性脑缺血发作(TIA)的预后表现。
在 916 例基线心电图无 AF 的非抗凝门诊稳定型 CHD 患者中,我们计算了 CHADS₂ 评分(充血性心力衰竭、高血压、年龄≥75 岁、糖尿病[各记 1 分]、既往卒中和 TIA[各记 2 分])。主要结局为平均随访 6.4±2.3 年后的缺血性卒中和 TIA 时间。
在 5821 人年的随访中,40 例患者发生缺血性卒中和 TIA(发生率为 0.69/100 人年,95%CI 为 0.50-0.94)。与低(0-1)CHADS₂ 评分患者相比,中(2-3)和高(4-6)CHADS₂ 评分患者的卒中/TIA 发生率更高,即使在校正年龄、烟草、抗血小板治疗、他汀类药物和血管紧张素抑制剂后(CHADS₂ 评分 2-3:HR 2.4,95%CI 1.1-5.3,P=0.03;CHADS₂ 评分 4-6:HR 4.0,95%CI 1.5-10.6,P=0.006)。模型区分度(C 统计量=0.65)与发表的仅 AF 队列中的 CHADS₂ 模型拟合相当。
CHADS₂ 评分可预测稳定型 CHD 且无基线 AF 的患者发生缺血性卒中和 TIA。高 CHADS₂ 评分(5-6)患者的事件发生率与发表的中度 CHADS₂ 评分(1-2)AF 患者的发生率相当,后者已知可从卒中预防治疗中获益。这些发现应有助于确定卒中预防治疗或筛查无症状 AF 是否可能使稳定型 CHD 且 CHADS₂ 评分较高的患者获益。